Comparative Pharmacology
Head-to-head clinical analysis: DEXLANSOPRAZOLE versus NEXIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXLANSOPRAZOLE versus NEXIUM.
DEXLANSOPRAZOLE vs NEXIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme (proton pump) at the secretory surface of gastric parietal cells. It is the S-isomer of omeprazole and is a weak base that accumulates in the acidic environment of the parietal cell canaliculi, where it is converted to the active sulfenamide form that binds covalently to the proton pump, irreversibly inhibiting acid secretion.
30 mg orally once daily for 4 weeks for healing of erosive esophagitis; maintenance therapy: 30 mg orally once daily for up to 6 months. For GERD: 30 mg orally once daily for 4 weeks.
20-40 mg orally once daily; IV: 20 mg once daily.
None Documented
None Documented
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Technetium Tc-99m medronate
"The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderate1-2 hours; clinical context: duration of acid suppression exceeds half-life due to binding to proton pumps
Approximately 1–1.5 hours in extensive CYP2C19 metabolizers; in poor metabolizers, half-life can be prolonged to 2–3 hours. Clinically, the plasma half-life does not directly correlate with the duration of acid suppression due to prolonged binding to the proton pump.
Renal: 0% unchanged; metabolites eliminated via urine (51%) and feces (48%)
Primarily hepatic metabolism via CYP2C19 and CYP3A4; approximately 80% of metabolites excreted in urine, and the remainder in feces via biliary elimination. Less than 1% of unchanged drug is excreted in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor
Dexlansoprazole + Pamidronic acid
"The therapeutic efficacy of Pamidronic acid can be decreased when used in combination with Dexlansoprazole."